광선각화증 치료 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the actinic keratosis treatment market size is expected to grow from USD 7.18 billion in 2025 to USD 7.47 billion in 2026 and is forecast to reach USD 9.13 billion by 2031 at 4.10% CAGR over 2026-2031.

This report is Segmented by Therapy (Topical Medications, and More), End User (Hospitals & Oncology Centers, and More), Distribution Channel (Hospital Pharmacies, and More), Patient Age Group (60 Years), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Actinic Keratosis Treatment Market Trends and Insights

Rising Prevalence of Actinic Keratosis Among Aging, Fair-Skinned Populations

Prevalence rates range from 11% to 25% in northern latitudes and reach 60% among Australian adults, underscoring a large and rising patient pool. Spain's clinic data show 28.6% overall prevalence, with men disproportionately affected, which shapes therapy demand. Improved public screening and longer life expectancy push more lesions into clinical settings, while each lesion signals elevated squamous cell carcinoma risk-with malignant transformation estimated at 8% in immunocompetent patients. Payers view early treatment as cost-avoiding, supporting broader coverage for both topical and procedural care. Collectively these dynamics create durable demand across every major geography.

Growing Demand for Minimally-Invasive Dermatologic Procedures

Patient preference is shifting toward approaches that offer high clearance and minimal downtime. Photodynamic therapy achieves 85%-90% clearance after one or two sessions and outperforms cryotherapy on cosmetic outcome. Daylight protocols lower pain scores and cut clinic occupancy, making the modality more acceptable to pain-averse patients. Fractional laser platforms such as the dual-wavelength Fraxel FTX deliver targeted ablation with faster recovery, driving procedural uptake. AI screening tools that hit 87% sensitivity accelerate early diagnosis, enabling doctors to select minimally invasive options sooner. Together these advances propel the procedural segment's rapid growth.

Adverse-Event Profile of Existing Topicals Limits Patient Compliance

Local reactions such as erythema, pain, and crusting cause many patients to discontinue 5-fluorouracil prematurely, hampering clearance outcomes. Ingenol mebutate's 2020 market exit after safety alarms magnified prescriber caution about newer molecules. Field-directed regimens often require covering large facial or scalp regions, creating visible inflammation that deters cosmetically sensitive patients. Ongoing studies exploring 5-FU-calcipotriene combinations aim to shorten treatment to four days while preserving high efficacy. Until tolerability improves, some patients will defer or refuse needed therapy.

Other drivers and restraints analyzed in the detailed report include:

1. Expansion of Reimbursement Coverage for AK Therapies in OECD Markets
2. Adoption of Daylight-PDT Protocols Reducing Chair-Time & Cost
3. Regulatory Approvals of Novel Agents Boosting Physician Uptake
4. AI-Enabled Dermoscopy Driving Earlier Diagnosis & Treatment Volumes
5. High Out-of-Pocket Costs in Emerging Economies

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Topical medications held 45.12% of actinic keratosis treatment market share in 2025 as 5-fluorouracil, imiquimod, and newer tirbanibulin remain first-line for field therapy . Tirbanibulin's label expansion to 100 cm2 positions it for wider facial and scalp application, reinforcing topical leadership. Nonetheless, the procedural category is on a 5.12% CAGR trajectory, and its share of the actinic keratosis treatment market size is forecast to rise steadily toward 2031. Daylight-mediated PDT, fractional CO2 lasers, and laser-assisted drug delivery are broadening the armamentarium, offering cosmetic advantages and shorter healing windows.

Procedural uptake varies by geography and reimbursement, yet clinical evidence continues to favor PDT over repeat topical courses for multi-lesion fields. Hospitals, dermatology clinics, and even ambulatory centers are investing in RhodoLED XL and similar platforms following recent FDA clearance. Cryotherapy, still widely used for isolated lesions, now competes with laser resurfacing that can remove diffuse ultraviolet damage in a single visit. As protocols mature, procedural treatments are expected to further dilute topical dominance, especially in markets where payers reward long-term clearance.

Hospitals and oncology centers accounted for 53.55% of actinic keratosis treatment market revenue in 2025, reflecting concentrated expertise and equipment-intensive procedures. Comprehensive reimbursement support and academic trial activity solidify their role in managing advanced or high-risk lesions. These facilities deploy integrated EHR, imaging, and AI triage that streamline field treatment mapping and follow-up. Nevertheless, capacity constraints and high overhead spur providers to triage stable cases into outpatient and home settings.

Home-care settings, aided by nurse-led phototherapy programs and self-applied topicals, are the fastest-growing channel at a 4.73% CAGR. Pilot programs demonstrate safe self-administration of narrow-band phototherapy and daylight-based PDT under virtual supervision, trimming transport and waiting costs. Teledermatology follow-up and app-based adherence reminders are critical enablers. As payers reimburse remote monitoring codes, home-care uptake is expected to accelerate, especially for maintenance and field therapies that do not require specialized devices.

Complete Report Scope:

• By Therapy
  • Topical Medications
    • 5-Fluorouracil
    • Imiquimod
    • Tirbanibulin
    • Diclofenac
    • Ingenol Mebutate
    • Other Topicals
  • Procedural Treatments
    • Cryotherapy
    • Photodynamic Therapy
    • Laser Resurfacing
    • Chemical Peels
    • Curettage & Electrodessication
    • Other Procedures
  • Combination / Sequential Therapy
• By End User
  • Hospitals & Oncology Centers
  • Dermatology Clinics
  • Ambulatory Surgical Centers
  • Home-care Settings
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Patient Age Group
  • < 40 Years
  • 40 - 60 Years
  • > 60 Years
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 41.70% of the actinic keratosis treatment market in 2025, supported by insurance coverage that reimburses multiple AK therapies, advanced research infrastructure, and rapid uptake of AI diagnostic platforms. Academic centers in the United States spearhead trials for laser-assisted drug delivery and combination topicals, reinforcing regional technology leadership. Canada mirrors these trends through universal healthcare and robust dermatologist density. Ongoing consolidation may enhance purchasing power and accelerate technology roll-outs.

Asia-Pacific, expanding at 6.08% CAGR, benefits from demographic aging and growing middle-class health spending, yet faces specialist shortages in emerging economies. Japan illustrates the aging burden, with 74% of skin cancer patients now over 70 years. Australia sets procedural adoption benchmarks, especially for daylight-PDT. China and India witness double-digit growth in teledermatology startups, though uneven reimbursement and limited dermatologist distribution restrain full-market potential. Regional AI algorithm developers work to recalibrate models for darker skin phototypes, which differ from Western training datasets.

Europe remains a mature yet innovative arena. National health services endorse daylight-PDT, and bundled-payment pilots in Germany and the Nordics test cost-containment for dermatology episodes. The EMA's decisive removal of ingenol mebutate underscores stringent safety oversight. Providers adjust formularies toward safer, evidence-heavy agents and invest in multi-wavelength laser workstations. Southern European countries, with higher UV indexes, allocate public funding to seasonal skin-cancer screening campaigns that feed procedure volumes during peak summer months.

1. Bausch Health
2. Almirall S.A.
3. Biofrontera
4. Sun Pharmaceuticals Industries
5. Galderma
6. Alma Lasers
7. Hill Dermaceuticals Inc.
8. GlaxoSmithKline
9. Cipher Pharmaceuticals
10. Leo Pharma
11. Novartis
12. DUSA Pharmaceuticals Inc.
13. Athenex Inc.
14. Theralase Technologies
15. Cutera
16. Hologic
17. ThermiGen
18. Valeant Pharmaceuticals Int'l
19. Regeneron Pharmaceuticals
20. Sanofi

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Prevalence Of Actinic Keratosis Among Aging, Fair-Skinned Populations
  • 4.2.2 Growing Demand For Minimally-Invasive Dermatologic Procedures
  • 4.2.3 Expansion Of Reimbursement Coverage For AK Therapies In OECD Markets
  • 4.2.4 Adoption Of Daylight-Pdt Protocols Reducing Chair-Time & Cost
  • 4.2.5 Regulatory Approvals Of Novel Agents Boosting Physician Uptake
  • 4.2.6 AI-Enabled Dermoscopy Driving Earlier Diagnosis & Treatment Volumes
• 4.3 Market Restraints
  • 4.3.1 Adverse-Event Profile Of Existing Topicals Limits Patient Compliance
  • 4.3.2 High Out-Of-Pocket Costs In Emerging Economies
  • 4.3.3 Withdrawal Of Ingenol Mebutate Eroding Clinician Confidence
  • 4.3.4 Margin Pressure From European Bundled-Payment Pilots
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts

• 5.1 By Therapy
  • 5.1.1 Topical Medications
    • 5.1.1.1 5-Fluorouracil
    • 5.1.1.2 Imiquimod
    • 5.1.1.3 Tirbanibulin
    • 5.1.1.4 Diclofenac
    • 5.1.1.5 Ingenol Mebutate
    • 5.1.1.6 Other Topicals
  • 5.1.2 Procedural Treatments
    • 5.1.2.1 Cryotherapy
    • 5.1.2.2 Photodynamic Therapy
    • 5.1.2.3 Laser Resurfacing
    • 5.1.2.4 Chemical Peels
    • 5.1.2.5 Curettage & Electrodessication
    • 5.1.2.6 Other Procedures
  • 5.1.3 Combination / Sequential Therapy
• 5.2 By End User
  • 5.2.1 Hospitals & Oncology Centers
  • 5.2.2 Dermatology Clinics
  • 5.2.3 Ambulatory Surgical Centers
  • 5.2.4 Home-care Settings
• 5.3 By Distribution Channel
  • 5.3.1 Hospital Pharmacies
  • 5.3.2 Retail Pharmacies
  • 5.3.3 Online Pharmacies
• 5.4 By Patient Age Group
  • 5.4.1 < 40 Years
  • 5.4.2 40 - 60 Years
  • 5.4.3 > 60 Years
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 Bausch Health Companies Inc.
  • 6.3.2 Almirall S.A.
  • 6.3.3 Biofrontera AG
  • 6.3.4 Sun Pharmaceutical Industries Ltd.
  • 6.3.5 Galderma SA
  • 6.3.6 Alma Lasers
  • 6.3.7 Hill Dermaceuticals Inc.
  • 6.3.8 GlaxoSmithKline plc
  • 6.3.9 Cipher Pharmaceuticals Inc.
  • 6.3.10 LEO Pharma A/S
  • 6.3.11 Novartis AG
  • 6.3.12 DUSA Pharmaceuticals Inc.
  • 6.3.13 Athenex Inc.
  • 6.3.14 Theralase Technologies Inc.
  • 6.3.15 Cutera Inc.
  • 6.3.16 Hologic Inc.
  • 6.3.17 ThermiGen LLC
  • 6.3.18 Valeant Pharmaceuticals Int'l
  • 6.3.19 Regeneron Pharmaceuticals Inc.
  • 6.3.20 Sanofi SA

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment